US 10076536
Oligonucleotide analogues targeting human LMNA
granted A61KA61K31/713A61K47/6455
Quick answer
US patent 10076536 (Oligonucleotide analogues targeting human LMNA) held by Sarepta Therapeutics, Inc. expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sarepta Therapeutics, Inc.
- Grant date
- Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/713, A61K47/6455, A61P, A61P43/00